Biocon Biologics To Close Viatris Deal Soon, Ipo Plan Likely In 12-24 Months

Biocon Biologics To Close Viatris Deal Soon, IPO Plan Likely In 12-24 Months

Biocon To Buy Viatris' Assets | Kiran Shaw On The Deal Rationale

Press Meet: Biocon Biologics To Acquire Viatris' Biosimilars Business For Global Leadership

Biocon Biologics

Biocon Biologics to Acquire Viatris Global Biosimilars Assets for upto USD 3.335 bn in stock & cash

Biocon Biologics

Biocon Biologics: Revolutionizing Healthcare with Biosimilars

Biocon Biologics

Biocon Biologics is well-placed to take advantage of opportunities in the biosimilars space: CEO

CNBC International News

Biocon Acquires Viatris' Biosimilars Biz: Kiran Mazumdar-Shaw On Deal Rationale & Growth Road Map

Biocon Biologics to acquire Viatris Inc's biosimilars business

The Hindu businessline

Why Is BOFA Bullish On Biocon?

Biocon Biologics's Shreehas Tambe Speaks On US FDA's Observation | Bazaar Open Exchange | CNBC-TV18

Biocon Goes Shopping

Biocon Sells 5.4% Stake In Syngene To Fund Viatris Biologics Biz Acquisition | Halftime Report

Biocon Biologics' Management On Acquiring Biosimilars Business Of Viatris

Biocon Biologics: Enabling Equitable Access to Affordable Healthcare

Biocon Biologics

Serum takes its investment in Biocon Bio to $300 Million, Kiran M Shaw On This & More | CNBC-TV18

Biocon Biologics Names Shreehas Tambe as New MD, CEO

Medical Dialogues

Biocon Biologics: Strong Earnings In Q2, What's Expansion & Capex Utilisation Plans?; Shreehas Tambe

Biocon Biologics' Shreehas Tambe Speaks On The Firm's Deal With Japan's Yoshindo | CNBC-TV18

Will list German arm Syngene in next 12 months: Biocon

NDTV Profit Markets